Kaycee Burcham, MD
Internal Medicine · Corinth, MSNPI 1518464080
Payments from drug & device makers
Across 281 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$740
- AbbVie$505
- Novo Nordisk$423
- Otsuka America Pharmaceutical, Inc.$404
- GSK$390
- AstraZeneca$387
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,504100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 51 | $740 |
| AbbVie | 42 | $505 |
| Novo Nordisk | 33 | $423 |
| Otsuka America Pharmaceutical, Inc. | 16 | $404 |
| GSK | 28 | $390 |
| AstraZeneca | 12 | $387 |
| Lilly USA, LLC | 16 | $254 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $209 |
| Boehringer Ingelheim | 9 | $164 |
| Amgen | 11 | $161 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $157 |
| Abbott | 6 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $109 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $79 |
| Johnson & Johnson | 4 | $65 |
| Idorsia Pharmaceuticals US Inc | 4 | $53 |
| Biohaven Pharmaceuticals, Inc. | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Merck | 2 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Genentech USA, Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Edwards Lifesciences | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,504 in reported general payments places this provider in the 85th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 11 | $134,204 |
| OzempicSemaglutide | 91 | $125,311 |
| EliquisApixaban | 175 | $97,662 |
| FarxigaDapagliflozin Propanediol | 94 | $80,061 |
| MounjaroTirzepatide | 38 | $42,227 |
| VraylarCariprazine Hcl | 22 | $42,215 |
| JardianceEmpagliflozin | 64 | $37,453 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $33,729 |
| OtezlaApremilast | 13 | $30,959 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $29,081 |
| XareltoRivaroxaban | 49 | $24,923 |
| EntrestoSacubitril/Valsartan | 22 | $24,573 |
| MyrbetriqMirabegron | 46 | $23,266 |
| RexultiBrexpiprazole | 13 | $18,896 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $18,863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Eliquis, Premarin | $740 | $236,969199 claims |
| Novo NordiskOzempic, Rybelsus | $423 | $144,159105 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $387 | $96,488118 claims |
| AbbVieVraylar, Linzess | $505 | $60,61348 claims |
| Boehringer IngelheimJardiance, Tradjenta | $164 | $45,46284 claims |
| Lilly USA, LLCMounjaro | $254 | $42,22738 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $390 | $41,12164 claims |
| AmgenOtezla | $161 | $30,95913 claims |
| Johnson & JohnsonXarelto | $65 | $24,92349 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $404 | $18,89613 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $109 | $12,58213 claims |
| MerckJanumet | $28 | $11,80913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Corinth
- Paul VolanskyCorinth$15K
- Timothy NoyesCorinth$14K
- Sophia ThangCorinth$12K
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.